VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Monday, January 5, 2026
Stock Comparison
Bristol-Myers Squibb Company vs Deutsche Boerse AG
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Bristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisDeutsche Boerse AG
DB1 · Xetra
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Deutsche Boerse AG's moat claims, evidence, and risks.
View DB1 analysisComparison highlights
- Moat score gap: Deutsche Boerse AG leads (81 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)); Deutsche Boerse AG has 8 segments (28.2% in Securities Services (Clearstream: ICSD/CSD settlement + custody)).
- Primary market structure: Oligopoly vs Duopoly. Pricing power: Moderate vs Moderate.
- Moat breadth: Bristol-Myers Squibb Company has 4 moat types across 3 domains; Deutsche Boerse AG has 12 across 5.
Primary market context
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
Deutsche Boerse AG
Securities Services (Clearstream: ICSD/CSD settlement + custody)
Securities settlement and custody infrastructure (ICSD/CSD) for Eurobonds and domestic markets
Global (Eurobonds + multiple domestic markets)
Custodian banks, broker-dealers, central banks, institutional investors
Settlement/custody infrastructure and asset servicing
28.2%
Side-by-side metrics
Moat coverage
Shared moat types
Bristol-Myers Squibb Company strengths
Deutsche Boerse AG strengths
Segment mix
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Deutsche Boerse AG segments
Full profile >Financial Derivatives (Eurex trading + Eurex Clearing)
Oligopoly
Commodities (EEX marketplaces + clearing)
Oligopoly
Cash Equities (Xetra + Boerse Frankfurt)
Quasi-Monopoly
FX & Digital Assets (360T + Crypto Finance)
Competitive
Securities Services (Clearstream: ICSD/CSD settlement + custody)
Duopoly
Fund Services (Vestima fund processing + Fund Centre distribution)
Oligopoly
Software Solutions (SimCorp + Axioma Analytics)
Competitive
ESG & Index (ISS STOXX: indices + ESG/governance data)
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.